Can Angiogenesis be a Target of Treatment for Ribavirin Associated Hemolytic Anemia?

Yonem O., Arslan S., Sokmensuer C., Salmanzade S.

HEPATO-GASTROENTEROLOGY, vol.57, pp.562-566, 2010 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 57
  • Publication Date: 2010
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.562-566
  • Hacettepe University Affiliated: Yes


Background/Aims: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis. We aimed to investigate whether there is a relation between hemoglobin, haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against anemia.